Skip to main content
Retour
Watch Compare

PLUS THERAPEUTICS, INC.

Qualité des données : 100%
PSTV
Nasdaq Manufacturing Measuring & Analyzing Instruments
3,82 €
▲ 0,65 € (20,50%)
Cap. Boursière: 26,21 M
Prix
3,82 €
Cap. Boursière
26,21 M
Fourchette du Jour
3,13 € — 4,10 €
Fourchette 52 Semaines
2,90 € — 30,50 €
Volume
787 304
Ouverture 3,13 €
Moyenne 50J / 200J
6,41 €
40,39% below
Moyenne 50J / 200J
11,39 €
66,45% below

Quick Summary

Points Clés

Negative free cash flow of -20,84 M
Capital efficient — spends only 1,29% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)-10,49%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-553,56%
En dessous de la moyenne du secteur (-53,41%)
ROIC-298,85%
Net Margin-429,43%
Op. Margin-293,46%

Sécurité

Debt / Equity
N/A
Current Ratio1,29
Interest Coverage-27,92

Valorisation

PE (TTM)
-1,17
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio5,19
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -1,2 -1,5
P/B 5,2 1,6
ROE % -553,6 -53,4
Net Margin % -429,4 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -10,49% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 5,21 M Net Income (TTM) -22,39 M
ROE -553,56% ROA -154,28%
Gross Margin N/A Operating Margin -293,46%
Net Margin -429,43% Free Cash Flow (TTM) -20,84 M
ROIC -298,85% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,29
Interest Coverage -27,92 Asset Turnover 0,36
Working Capital 3,97 M Tangible Book Value 4,68 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,17 Forward P/E N/A
P/B Ratio 5,19 P/S Ratio 5,03
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -79,51%
Market Cap 26,21 M Enterprise Value 12,92 M
Per Share
EPS (Diluted TTM) -0,29 Revenue / Share 0,76
FCF / Share -3,04 OCF / Share -3,03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,29% FCF Conversion 93,10%
SBC-Adj. FCF -21,79 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5,21 M 5,82 M — — —
Net Income -22,39 M -12,98 M -13,32 M -20,28 M -13,40 M
EPS (Diluted) -0,29 -2,34 -4,24 -0,77 —
Gross Profit — — — — —
Operating Income -15,30 M -14,70 M -13,32 M -19,71 M -12,49 M
EBITDA — — — — —
R&D Expenses 8,38 M 10,58 M 9,69 M — —
SG&A Expenses — — — — —
D&A 445 000,0 723 000,0 628 000,0 619 000,0 395 000,0
Interest Expense 548 000,0 179 000,0 395 000,0 711 000,0 932 000,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 16,33 M 6,63 M 11,39 M 23,87 M 21,98 M
Total Liabilities 12,33 M 15,58 M 12,74 M 17,42 M 11,15 M
Shareholders' Equity 4,00 M -8,95 M -1,35 M 6,45 M 10,84 M
Total Debt — — 3,79 M 3,79 M 5,01 M
Cash & Equivalents 4,26 M 76 000,0 8,55 M 18,12 M 18,40 M
Current Assets 15,17 M 5,26 M 9,83 M 21,82 M 19,72 M
Current Liabilities 12,31 M 15,55 M 10,73 M 11,85 M 5,87 M